Drug Details
| General Information of the Drug (ID: DR5481) | ||||
|---|---|---|---|---|
| Name |
3-bromopyruvate
|
|||
| Synonyms |
3-bromopyruvic acid; bromopyruvic acid; 1113-59-3; 3-bromo-2-oxopropanoic acid; 3-Bromo-2-oxopropionic acid; bromopyruvate; 3-bromopyruvate; Bromopyruvicacid; Pyruvic acid, bromo-; Propanoic acid, 3-bromo-2-oxo-; UNII-63JMV04GRK; MFCD00002587; .beta.-Bromopyruvic acid; 63JMV04GRK; 3-bromo-2-oxo-propionic acid; C3H3BrO3; 3-BrPA; EINECS 214-206-5; NSC 11731; NSC 62343; BRN 1746786; BPV; bromo-2-oxopropanoic acid; ACMC-1C0WT; SCHEMBL8126; NCIOpen2_000241; 3-BP; 3-bromo-2-keto-propionic acid; CHEMBL177837; 3-Bromo-2-oxopropanoic acid #; 3-Bromopyruvic acid hydrate,98; DTXSID7040940; CHEBI:95046; CHEBI:131461; Hexokinase II Inhibitor II;3-BP; HMS3741K19; HMS3866H13; ACT09279; NSC11731; NSC62343; ZINC1718542; ANW-43645; NSC-11731; NSC-62343; NSC782120; s5426; SBB053571; Bromopyruvic acid, >=97.0% (T); AKOS015892643; AM84337; CCG-266336; CS-5517; MCULE-4768170572; NSC-782120; AS-16146; DA-15474; HY-19992; S691; AK00558616; B1153; FT-0623262; ST51037166; EN300-67360; A-2150; Bromopyruvic acid; 3-bromo-2-oxopropanoic acid; J-511892; J-650255; Q3608257; BRD-K92980438-001-01-7; Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3; Z2690354216
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C3H3BrO3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C(C(=O)C(=O)O)Br
|
|||
| InChI |
1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)
|
|||
| InChIKey |
PRRZDZJYSJLDBS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1113-59-3
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Delphinidin | Aristotelia chilensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | PEO1 | CVCL_2686 | BRCA2 syndrome | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Delphinidin increases the sensitivity of ovarian cancer cell lines to 3-bromopyruvate. | |||||
| Methyl jasmonate | Jasminum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
| In-vivo Model | BALB/c inbred female mice were used in this study. | |||||
| Experimental
Result(s) |
This combination therapy didn't have any noticeable side effects on kidney, liver, and immune system and body weight. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein 1S (MAP1S) | Molecule Info | [4] | |